ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Systemic, Targeted, & Immune Therapies

PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays

on: April 05, 2018In: Systemic, Targeted, & Immune Therapies
PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays

By Fred R. Hirsch, MD, PhD Posted: April 2018 Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of its refinement, we struggle […] Read more


PACIFIC Trial Leads to Durvalumab Approval in United States

on: April 05, 2018In: Systemic, Targeted, & Immune Therapies
PACIFIC Trial Leads to Durvalumab Approval in United States

The U.S. Food and Drug Administration approved durvalumab on February 16, 2018, for the treatment of patients with stage III NSCLC whose tumors are unresectable and whose cancer has not […] Read more

Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC

on: February 19, 2018In: Systemic, Targeted, & Immune Therapies
Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in
            NSCLC

By Hossein Borghaei, MS, DO Posted: February 2018 The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For patients who are treatment […] Read more

ALK Testing in Europe

on: February 19, 2018In: Systemic, Targeted, & Immune Therapies
ALK Testing in Europe

By Enriqueta Felip, MD, PhD Posted: February 2018 ALK-directed TKIs are effective first- and second-line therapies in patients with ALK rearrangements. Testing of all patients with stage IV adenocarcinomas of […] Read more

Immunotherapy Adverse-Event Treatment Resource Guide

on: February 19, 2018In: Systemic, Targeted, & Immune Therapies
Immunotherapy Adverse-Event Treatment Resource Guide

The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline to support nurses and allied health […] Read more

Management of Immunotherapy Toxicity in NSCLC

on: February 19, 2018In: Systemic, Targeted, & Immune Therapies
Management of Immunotherapy Toxicity in NSCLC

By Beth Eaby-Sandy, MSN, CRNP Posted: February 2018 When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was focused and streamlined. Chemotherapy […] Read more

ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer

on: September 28, 2017In: Systemic, Targeted, & Immune Therapies
ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer

By Heather Wakelee, MD Posted: October 2017 For most of the world, four cycles of cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II and […] Read more

Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations

on: September 28, 2017In: Systemic, Targeted, & Immune Therapies
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung
            Cancer With EGFR-Activating Mutations

By Cynthia L. Kryder, MS, CCC-Sp Editor Note: IASLC Lung Cancer News is pleased to provide the following overview, which is followed by expert commentary by Dr. Heather Wakelee, Dr. […] Read more

Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations

on: September 28, 2017In: Systemic, Targeted, & Immune Therapies
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung
            Cancer With EGFR-Activating Mutations

By Julien Mazieres, MD, PhD Posted: October 2017 The standard of care for patients postresection for lung cancer is adjuvant chemotherapy, usually a platinum-based regimen.1 The deciphering of lung oncogenesis […] Read more

Q & A with Yi-Long Wu, MD

on: September 28, 2017In: Systemic, Targeted, & Immune Therapies
Q & A with Yi-Long Wu, MD

What is the current standard of care in the adjuvant setting post-resection of high-risk NSCLC in your practice or nationally?Posted: October 2017 Current Chinese Lung Cancer Diagnosis and Treatment Guideline […] Read more

123456

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy